Are you Dr. Kerstein?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 5 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1 Boston Medical Ctr Pl
Yawkey Basement, Bn C7
Boston, MA 02118Phone+1 617-414-5423Fax+1 617-638-6744
Clinical Trials
- A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Start of enrollment: 2014 Jun 04
- ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2016 May 26
- An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Publications & Presentations
PubMed
- 6 citationsConverting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.Ariane K. Kawata, William R. Lenderking, Olabimpe R. Eseyin, David Kerstein, Joice Huang
Journal of Medical Economics. 2019-06-25 - 15 citationsThe Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.Meera Tugnait, Neeraj Gupta, Michael J. Hanley, Karthik Venkatakrishnan, Daryl Sonnichsen
Clinical Pharmacology in Drug Development. 2019-08-01
Press Mentions
Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical OfficerNovember 26th, 2018
Takeda Announces Positive Phase 3 ALTA-1L Data in First-Line Therapy for Advanced ALK+ NSCLCOctober 22nd, 2018
Takeda Präsentiert Ergebnisse Aus Der Phase-3-Studie ALTA-1L, Die Die Intrakranielle Wirksamkeit Von ALUNBRIGOctober 20th, 2018- Join now to see all
